Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma

Matthias A. Karajannis, Audrey Mauguen, Ekrem Maloku, Qingwen Xu, Erin M. Dunbar, Scott R. Plotkin, Anna Yaffee, Shiyang Wang, J. Thomas Roland, Chandranath Sen, Dimitris G. Placantonakis, John G. Golfinos, Jeffrey C. Allen, Nicholas A. Vitanza, Luis A. Chiriboga, Robert J. Schneider, Jingjing Deng, Thomas A. Neubert, Judith D. Goldberg, David ZagzagFilippo G. Giancotti, Jaishri O. Blakeley

Research output: Contribution to journalArticlepeer-review


Inhibition of mTORC1 signaling has been shown to diminish growth of meningiomas and schwannomas in preclinical studies, and clinical data suggest that everolimus, an orally administered mTORC1 inhibitor, may slow tumor progression in a subset of patients with neurofibromatosis type 2 (NF2) with vestibular schwannoma. To assess the pharmacokinetics, pharmacodynamics, and potential mechanisms of treatment resistance, we performed a presurgical (phase 0) clinical trial of everolimus in patients undergoing elective surgery for vestibular schwannoma or meningiomas. Eligible patients with meningioma or vestibular schwannoma requiring tumor resection enrolled on study received everolimus 10 mg daily for 10 days immediately prior to surgery. Everolimus blood levels were determined immediately before and after surgery. Tumor samples were collected intraoperatively. Ten patients completed protocol therapy. Median pre- and postoperative blood levels of everolimus were found to be in a high therapeutic range (17.4 ng/mL and 9.4 ng/mL, respectively). Median tumor tissue drug concentration determined by mass spectrometry was 24.3 pg/mg (range, 9.2-169.2). We observed only partial inhibition of phospho-S6 in the treated tumors, indicating incomplete target inhibition compared with control tissues from untreated patients (P = 0.025). Everolimus led to incomplete inhibition of mTORC1 and downstream signaling. These data may explain the limited antitumor effect of everolimus observed in clinical studies for patients with NF2 and will inform the design of future preclinical and clinical studies targeting mTORC1 in meningiomas and schwannomas.

Original languageEnglish (US)
Pages (from-to)1584-1591
Number of pages8
JournalMolecular cancer therapeutics
Issue number9
StatePublished - Sep 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma'. Together they form a unique fingerprint.

Cite this